Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Freeport-McMoRan Inc. securities between February 15, 2022, and September 24, 2025, highlighting potential compensation for affected investors [2][3]. Group 1: Lawsuit Details - The lawsuit alleges that Freeport-McMoRan made false and misleading statements regarding safety at the Grasberg Block Cave mine in Indonesia, which posed a heightened risk to workers [6]. - It is claimed that the lack of proper safety measures could foreseeably lead to worker fatalities, resulting in undisclosed regulatory, litigation, and reputational risks [6]. - The lawsuit asserts that when the true details became public, investors suffered damages due to the misleading nature of the company's statements about its business and operations [6]. Group 2: Investor Actions - Investors who purchased Freeport-McMoRan securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - To participate in the class action, investors must move the Court by January 12, 2026, if they wish to serve as lead plaintiff [4]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [4][7]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm is recognized for its success in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking in the top for settlements since 2013 [5]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [5]. - The firm emphasizes the importance of selecting qualified counsel with a proven track record in securities litigation [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 29, 2025 deadline to serve as lead plaintiff, which involves directing the litigation on behalf of other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that DexCom's public statements regarding the enhancements and reliability of the G7 devices were materially false and misleading, leading to increased regulatory scrutiny and potential legal repercussions [5].

Core Insights - ReGen III Corp. has received settlement and exchange agreements totaling $3.975 million related to its Convertible Debenture Exchange, indicating strong support from debenture holders [1][2] - The company aims to commercialize sustainable, re-refined Group III base oils, with a nearly 100% agreement from debenture holders reflecting confidence in its strategic direction [2][4] Financial Developments - The company has successfully secured Sub-Agreements from over 97% of debenture holders, which strengthens its financial position [2] - The CD Exchange is expected to close immediately following final approval from the TSX Venture Exchange [2] Business Strategy - ReGen III is focused on transforming used motor oil into high-value Group II and III base oils, which are essential for high-performance engines and industrial applications [4] - The company’s patented ReGen™ technology is designed to reduce CO₂e emissions by up to 82% compared to virgin crude derived oils [4] Operational Updates - The company has completed FEL2 and value engineering for its proposed 5,600 bpd flagship facility in Texas City, Texas, positioning itself to meet rising demand for higher-quality, circular base oils [5] - ReGen III is exploring opportunities to deploy its technology in other strategic markets beyond Texas City [5] Vision and Market Position - The company aims to become the world's largest producer of sustainable, re-refined Group III base oils, setting a new standard for performance and responsibility in the lubricants market [6]

New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Firefly Aerospace Inc. (NASDAQ: FLY) resulting from allegations that Firefly Aerospace may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Firefly Aerospace securities you may be entitled to compensation without payment of any out of pocket fees or cos ...

Rouyn-Noranda, Quebec--(Newsfile Corp. - November 17, 2025) - Radisson Mining Resources Inc. (TSXV: RDS) (OTCQX: RMRDF) ("Radisson" or the "Company") is pleased to announce that it has received total gross proceeds of C$1,481,694.12 from the exercise of 5,487,756 class A shares purchase warrants (the "Warrants") at a price of $0.27 per warrant. The Warrants were issued in relation to a private placement completed in November 2023 and had an expiry of November 17, 2025.Furthermore, the Company has received ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Zions Bancorporation due to allegations of materially misleading business information issued to the public [1] Group 1: Legal Action and Investor Rights - Investors who purchased Zions Bancorporation securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2] Group 2: Financial Disclosure and Impact - On October 15, 2025, Zions Bancorporation announced a $50 million charge-off related to a loan from its subsidiary, California Bank & Trust, due to misrepresentations and contractual defaults [3] - Following this announcement, Zions Bancorporation's common stock experienced a decline of 13.14% on October 16, 2025 [4] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [5] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of Marex Group plc to secure legal counsel before the December 8, 2025 deadline for a securities class action lawsuit related to misleading financial statements and practices [1][5]. Group 1: Class Action Details - The class action pertains to investors who purchased Marex securities between May 16, 2024, and August 5, 2025, and may be entitled to compensation without upfront fees through a contingency fee arrangement [2][5]. - The lawsuit alleges that Marex made materially false statements and failed to disclose critical information regarding its financial practices, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in recent years [4].

Core Points - Sixty North Gold Mining Ltd. is closing the second and final tranche of its offering, consisting of 8,904,320 units for gross proceeds of $979,475.20, bringing total gross proceeds to $1,649,969.20 [1][4] - Each unit is priced at $0.11 and includes one common share and one non-transferable common share purchase warrant, exercisable at $0.15 for 24 months [2] - Finder's fees of $76,758 in cash and 697,800 finder's warrants were paid on portions of the second tranche [3] Financial Details - The total gross proceeds from both tranches of the offering amount to $1,649,969.20 [1] - The net proceeds will be allocated for exploration and development of the Mon Gold Property and general working capital [4] Company Overview - Sixty North Gold is developing mining operations at its 100% owned Mon Gold Project, which previously extracted 15,000 tonnes of ore, recovering an estimated 15,000 ounces of gold [5] - The North Ramp has been reopened and extended to target portions of the vein, with plans to develop stopes in various zones to support a 100 tpd gravity-flotation mill [5] - The Yellowknife gold camp has a history of significant gold production, with two mines averaging 30 gpt gold or better [6]

Core Insights - Cleantek Industries Inc. reported strong financial results for Q3 2025, highlighting resilience in a challenging North American market and effective execution of its business model [2][5]. Financial Performance - Revenue for Q3 2025 increased by 18% to CAD 3,282 thousand from CAD 2,779 thousand in Q3 2024, driven by market share gains in equipment rentals and international sales [5]. - Gross profit rose by 9% to CAD 1,889 thousand, representing 58% of revenue, compared to 62% in Q3 2024, with the decrease in gross margin attributed to changes in revenue mix and higher transportation costs [5]. - EBITDA surged by 105% to CAD 1,135 thousand from CAD 553 thousand in Q3 2024 [5]. - Adjusted EBITDA decreased by 2% to CAD 985 thousand, primarily due to adjustments related to asset disposals and unrealized foreign exchange impacts [5]. - Net income improved to CAD 352 thousand in Q3 2025, a significant increase from a net loss of CAD 211 thousand in Q3 2024, driven by higher revenue [5]. Operational Strategy - Looking ahead to Q4, Cleantek aims to pursue market share gains, international expansion, increased utilization, and iterative product development [3]. - The company emphasizes a lean cost structure and innovative products as a foundation for scalable growth in a rapidly evolving industry [3]. Company Overview - Cleantek is focused on providing patented clean technology solutions for wastewater management and industrial lighting, catering to a diverse client base, including major exploration and production companies across North America [7]. - The company is well-positioned to meet the rising demand for water treatment and sustainable lighting solutions, driven by its commitment to sustainability, safety, and operational excellence [7].

Core Viewpoint - Predictmedix AI Inc. successfully closed the first tranche of its non-brokered private placement, raising gross proceeds of $460,150 by issuing 9,203,000 units at a price of $0.05 per unit, indicating strong internal confidence in the company's future growth and innovation [1][2]. Financing Details - The private placement consisted of 9,203,000 units, each comprising one common share and one half of a common share purchase warrant, raising a total of $460,150 [2]. - Insiders subscribed $60,000 of the tranche, with Sheldon Kales and Dr. Rahul Kushwah each investing $30,000, reflecting confidence in the company's prospects [1][3]. - Each warrant allows the holder to purchase one half of a common share at a price of C$0.15 for 36 months, with potential acceleration of expiry if the share price meets certain conditions [2]. Regulatory Context - The insider participation in the private placement is classified as a "related party transaction" under Multilateral Instrument 61-101, with the company relying on exemptions from valuation and minority shareholder approval requirements [3]. Strategic Engagement - This financing round follows Predictmedix's active engagement with European capital markets, including participation in the 25th MK Investment Conference in Munich, aimed at expanding its shareholder base and building relationships with global investors [5]. - The company has also conducted a high-profile European road-show to engage influential family offices and institutional investors [5]. Company Overview - Predictmedix AI Inc. is an emerging provider of rapid health screening and remote patient care solutions, utilizing AI technology to analyze physiological data and predict various health issues [6]. - The company's Smarthealth AI stations can assess 19 physiological vital parameters and detect impairments due to drugs or alcohol, fatigue, or mental illnesses [6].